Open

Study on How Volrustomig Works with Other Cancer Drugs for Treating Tumors

The purpose of this study is to test how safe and effective Volrustomig is when combined with other cancer treatments for people with specific types of tumors, specifically in the lung(s). The goal is to see if this combination can help treat the tumors better while being safe for patients.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

You will attend study visits to receive chemotherapy along with the study drug. During these visits: - Your vitals will be taken. - You will be asked about your physical well-being.

Incentives

Study Drug

In-person visits:
All

Total length of participation:
24 months

Looking for Specific Volunteers

Able to participate:

Life expectancy of 12 weeks or longer
Adequate organ and bone marrow function
At least one measurable tumor

Not eligible if:

Active or prior documented autoimmune or inflammatory disorders
You have active brain mets
Spinal cord compression.

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clincal Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Shetal Patel
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lung)

IRB Number

24-1611

ClinicalTrials.gov

NCT06448754

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.